8-K: Calidi Biotherapeutics Amends Convertible Note, Settles Prior Funding Disputes

Calidi Biotherapeutics has amended a $1.5 million convertible note and settled disputes related to prior funding agreements by issuing new convertible notes.

Summary

• Calidi Biotherapeutics entered into a settlement agreement on March 8, 2024, to resolve disputes related to previous funding agreements.
• As part of the settlement, Calidi issued a $2.0 million convertible note for cash and a $1.5 million convertible note in exchange for settling all claims related to the prior agreements.
• Both convertible notes bear a 10% per annum interest rate, payable semi-annually, and mature on March 8, 2028.
• The notes can be converted into common stock at 94% of the 10-day VWAP before execution, with a reset price at 94% of the 10-day VWAP 30 days after the registration statement is effective.
• A mandatory conversion is triggered if Calidi raises at least $8 million in a registered offering or $2 million with a non-affiliated purchaser at 150% of the initial conversion price.
• On March 11, 2024, an amendment to the $1.5 million note removed the requirement for the principal amount to be wired to the company's bank account.

Sentiment

Score: 6

Explanation: The document indicates a resolution of past disputes and secures new funding, but also introduces potential dilution and debt obligations. The sentiment is neutral to slightly positive.

Positives

• The settlement resolves outstanding disputes related to prior funding agreements.
• The company secured $2.0 million in cash through the issuance of one of the convertible notes.
• The convertible notes provide a potential source of equity financing for the company.
• The amendment to the $1.5 million note simplifies the closing process.

Negatives

• The company has taken on additional debt through the issuance of the convertible notes.
• The conversion of the notes could dilute existing shareholders.
• The mandatory conversion feature could be triggered by future financing events, potentially leading to further dilution.
• The company is obligated to file a registration statement for the resale of shares issued upon conversion of the notes.

Risks

• The company may face challenges in meeting the conditions for mandatory conversion of the notes.
• The conversion of the notes could significantly dilute existing shareholders.
• The company's ability to raise additional capital may be affected by the terms of the convertible notes.
• The company is subject to potential penalties for failing to deliver shares on time after conversion.

Future Outlook

The company intends to file a registration statement for the resale of shares issued upon conversion of the notes, unless a registered public offering is completed by April 30, 2024. The company may also need to seek shareholder approval for conversions exceeding the Exchange Cap.

Management Comments

• The document includes signatures from Wendy Pizarro, Chief Legal Officer, and Allan Camaisa, Chief Executive Officer, indicating their approval of the agreements.

Industry Context

The use of convertible notes is a common financing method for biotech companies, especially those in the early stages of development. The settlement of prior funding disputes and the issuance of new convertible notes suggest the company is actively managing its capital structure and resolving past issues.

Comparison to Industry Standards

• The 10% interest rate on the convertible notes is within the typical range for early-stage biotech companies.
• The conversion terms, based on a percentage of VWAP, are also standard in the industry.
• The mandatory conversion feature is a common mechanism to incentivize investors and ensure the company can access equity capital.
• The inclusion of registration rights is a standard practice to provide liquidity to investors.

Stakeholder Impact

• Shareholders may experience dilution if the convertible notes are converted into common stock.
• Investors in the convertible notes have the potential to benefit from the conversion into equity.
• The company's creditors may be impacted by the new debt obligations.
• The settlement of prior disputes may improve the company's reputation with stakeholders.

Next Steps

• The company needs to file a registration statement for the resale of shares issued upon conversion of the notes.
• The company may conduct a registered public offering by April 30, 2024.
• The company may need to seek shareholder approval for conversions exceeding the Exchange Cap.

Key Dates

Keywords

convertible note, settlement agreement, funding, financing, common stock, conversion, registration statement, dilution, VWAP, mandatory conversion